US News And World Report Best Law Firms 2022
Richard J. Lambert was named by Best Lawyers® as a 2021 Corporate Law “Lawyer of the Year.”

Best Lawyers® is the oldest and most respected peer-review publication in the legal profession. Only one lawyer in each practice area in a given community is honored as “Lawyer of the Year.”


Comprehensive Legal Services For Businesses

In New Jersey And New York call


Comprehensive Legal Services For Businesses

In New Jersey And New York call

Dunn Lambert, LLC



Business Law Professionals

  1. Home
  2.  » 
  3. Commercial Litigation
  4.  » Intellectual property litigation settles in New Jersey court

Intellectual property litigation settles in New Jersey court

On Behalf of | Nov 19, 2012 | Commercial Litigation |

A New Jersey lawsuit has recently settled between Johnson & Johnson’s Janssen Pharmaceuticals unit and Mylan Inc. The commercial litigation involved a patent for Ortho Tri-Cycle Lo — a form of oral birth control — that made $424.5 million last year. This suit had been ongoing in a federal court in Newark since November 2010. In the suit, Janssen claimed that Mylan — a company based in Pittsburgh  had infringed on its patent.

With this settlement, the case between Janssen and Mylan will be dismissed. However, the settlement agreement can be reviewed by Federal Trade Commission and the U.S. Department of Justice. Under the terms of the settlement, Mylan will still be able to sell certain formulations of the generic birth control pill. However, other terms of the settlement were not released to the public.

An intellectual property dispute such as this one can be difficult for any New Jersey business to deal with. The terms of the settlement can be complex and affect many areas of the company’s business. Patents, in particular, are important to vigorously protect since much of a business’s revenue may come from a patented product, machine or invention. If other companies are allowed to use this protected property, money will be lost.

If not handled properly, commercial litigation can unnecessarily cost a company revenue. However, with the right help, settlements can be reached so that all parties can come to an acceptable solution. By settling, companies can avoid years of costly litigation while still protecting their business’s intellectual property.

Source: Bloomberg Businessweek, “AstraZeneca, Mylan, Hachettte: Intellectual Property,” Victoria Slind-Flor, Nov. 9, 2012